HUSCAP logo Hokkaido Univ. logo

Hokkaido University Collection of Scholarly and Academic Papers >
Hokkaido University Hospital >
Peer-reviewed Journal Articles, etc >

HB Vaccination in the Prevention of Viral Reactivation in Allogeneic Hematopoietic Stem Cell Transplantation Recipients with Previous HBV Infection

Files in This Item:
14-11_p1226-1230.pdf148.06 kBPDFView/Open
Please use this identifier to cite or link to this item:http://hdl.handle.net/2115/38729

Title: HB Vaccination in the Prevention of Viral Reactivation in Allogeneic Hematopoietic Stem Cell Transplantation Recipients with Previous HBV Infection
Other Titles: HB vaccine to prevent viral reactivation in allogeneic hematopoietic stem cell transplantation recipients with previous HBV infection
Authors: Onozawa, Masahiro Browse this author
Hashino, Satoshi Browse this author →KAKEN DB
Darmanin, Stephanie Browse this author
Okada, Kohei Browse this author
Morita, Rena Browse this author
Takahata, Mutsumi Browse this author
Shigematsu, Akio Browse this author
Kahata, Kaoru Browse this author
Kondo, Takeshi Browse this author
Tanaka, Junji Browse this author →KAKEN DB
Imamura, Masahiro Browse this author
Asaka, Masahiro Browse this author
Keywords: hepatitis B virus
reverse seroconversion
reactivation of hepatitis
vaccination
recombinant hepatitis B vaccine
Issue Date: Nov-2008
Publisher: Elsevier Inc.
Journal Title: Biology of Blood and Marrow Transplantation
Volume: 14
Issue: 11
Start Page: 1226
End Page: 1230
Publisher DOI: 10.1016/j.bbmt.2008.08.007
PMID: 18940676
Abstract: HBV-reverse seroconversion (RS) following allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a frequent late-onset complication in recipients with previous HBV infection. We conducted post-transplant HB vaccine intervention in 38 allo-HSCT recipients with previous HBV infection. Firstly, we followed the recipients without any intervention (historical control) until 2003; hence we commenced HB vaccination. Out of the patients who underwent transplantation after 2003, 13 recipients were immunized by a standard 3-dose regimen after immunosuppressant cessation (vaccine group), while 12 recipients were observed without any intervention (non-vaccine group). Eight of the 13 historical control group recipients and 3 of the 12 non-vaccine group recipients, but none of the 13 vaccine group recipients, suffered HBV-RS. Cumulative risks of HBV-RS at 3 years post-HSCT in the historical control, non-vaccine and vaccine groups were 41%, 39% and 0% respectively (P = 0.022). We therefore conclude that intervention with HB vaccines is significantly effective in preventing post-HSCT HBV-RS.
Type: article (author version)
URI: http://hdl.handle.net/2115/38729
Appears in Collections:北海道大学病院 (Hokkaido University Hospital) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)

Submitter: 小野澤 真弘

Export metadata:

OAI-PMH ( junii2 , jpcoar )

MathJax is now OFF:


 

Feedback - Hokkaido University